Natalia S Rost1, Lisa Cloonan2, Allison S Kanakis2, Kaitlin M Fitzpatrick2, Danielle R Azzariti2, Virginia Clarke2, Charles M Lourenco2, Dominique P Germain2, Juan M Politei2, György A Homola2, Claudia Sommer2, Nurcan Üçeyler2, Katherine B Sims2. 1. From the J. Philip Kistler Stroke Research Center, Department of Neurology (N.S.R., L.C., A.S.K., K.M.F.), and the Center for Human Genetic Research, Department of Neurology (N.S.R., D.R.A., V.C., K.B.S.), Massachusetts General Hospital, Boston; Neurogenetics Unit (C.M.L.), School of Medicine of Riberirao Preto, University of São Paulo, Brazil; Division of Medical Genetics (D.P.G.), University of Versailles-St Quentin en Yvelines Paris-Saclay University, France; Fundación para el Estudio de las Enfermedades Neurometabólicas (FESEN) (J.M.P.), Buenos Aires, Argentina; and Departments of Neuroradiology (G.A.H.) and Neurology (C.S., N.Ü.), Fabry Center for Interdisciplinary Therapy (FAZIT) (C.S., N.Ü.), University of Würzburg, Germany. nrost@partners.org. 2. From the J. Philip Kistler Stroke Research Center, Department of Neurology (N.S.R., L.C., A.S.K., K.M.F.), and the Center for Human Genetic Research, Department of Neurology (N.S.R., D.R.A., V.C., K.B.S.), Massachusetts General Hospital, Boston; Neurogenetics Unit (C.M.L.), School of Medicine of Riberirao Preto, University of São Paulo, Brazil; Division of Medical Genetics (D.P.G.), University of Versailles-St Quentin en Yvelines Paris-Saclay University, France; Fundación para el Estudio de las Enfermedades Neurometabólicas (FESEN) (J.M.P.), Buenos Aires, Argentina; and Departments of Neuroradiology (G.A.H.) and Neurology (C.S., N.Ü.), Fabry Center for Interdisciplinary Therapy (FAZIT) (C.S., N.Ü.), University of Würzburg, Germany.
Abstract
OBJECTIVE: Using a semiautomated volumetric MRI assessment method, we aimed to identify determinants of white matter hyperintensity (WMH) burden in patients with Fabry disease (FD). METHODS: Patients with confirmed FD and brain MRI available for this analysis were eligible for this protocol after written consent. Clinical characteristics were abstracted from medical records. T2 fluid-attenuated inversion recovery MRI were transferred in electronic format and analyzed for WMH volume (WMHV) using a validated, computer-assisted method. WMHV was normalized for head size (nWMHV) and natural log-transformed (lnWMHV) for univariate and multivariate linear regression analyses. Level of significance was set at p < 0.05 for all analyses. RESULTS: Of 223 patients with FD and WMHV analyzed, 132 (59%) were female. Mean age at MRI was 39.2 ± 14.9 (range 9.6-72.7) years, and 136 (61%) patients received enzyme replacement therapy prior to enrollment. Median nWMHV was 2.7 cm(3) (interquartile range 1.8-4.0). Age (β 0.02, p = 0.008) and history of stroke (β 1.13, p = 0.02) were independently associated with lnWMHV. However, WMH burden-as well as WMHV predictors-varied by decade of life in this cohort of patients with FD (p < 0.0001). CONCLUSIONS: In this largest-to-date cohort of patients with FD who had volumetric analysis of MRI, age and prior stroke independently predicted the burden of WMH. The 4th decade of life appears to be critical in progression of WMH burden, as novel predictors of WMHV emerged in patients aged 31-40 years. Future studies to elucidate the biology of WMH in FD and its role as potential MRI marker of disease progression are needed.
OBJECTIVE: Using a semiautomated volumetric MRI assessment method, we aimed to identify determinants of white matter hyperintensity (WMH) burden in patients with Fabry disease (FD). METHODS:Patients with confirmed FD and brain MRI available for this analysis were eligible for this protocol after written consent. Clinical characteristics were abstracted from medical records. T2 fluid-attenuated inversion recovery MRI were transferred in electronic format and analyzed for WMH volume (WMHV) using a validated, computer-assisted method. WMHV was normalized for head size (nWMHV) and natural log-transformed (lnWMHV) for univariate and multivariate linear regression analyses. Level of significance was set at p < 0.05 for all analyses. RESULTS: Of 223 patients with FD and WMHV analyzed, 132 (59%) were female. Mean age at MRI was 39.2 ± 14.9 (range 9.6-72.7) years, and 136 (61%) patients received enzyme replacement therapy prior to enrollment. Median nWMHV was 2.7 cm(3) (interquartile range 1.8-4.0). Age (β 0.02, p = 0.008) and history of stroke (β 1.13, p = 0.02) were independently associated with lnWMHV. However, WMH burden-as well as WMHV predictors-varied by decade of life in this cohort of patients with FD (p < 0.0001). CONCLUSIONS: In this largest-to-date cohort of patients with FD who had volumetric analysis of MRI, age and prior stroke independently predicted the burden of WMH. The 4th decade of life appears to be critical in progression of WMH burden, as novel predictors of WMHV emerged in patients aged 31-40 years. Future studies to elucidate the biology of WMH in FD and its role as potential MRI marker of disease progression are needed.
Authors: Karen J Ferguson; Joanna M Wardlaw; C Louise Edmond; Ian J Deary; Alasdair M J Maclullich Journal: J Neuroimaging Date: 2005-01 Impact factor: 2.486
Authors: L Echevarria; K Benistan; A Toussaint; O Dubourg; A A Hagege; D Eladari; F Jabbour; C Beldjord; P De Mazancourt; D P Germain Journal: Clin Genet Date: 2015-06-22 Impact factor: 4.438
Authors: Y W Chen; M E Gurol; J Rosand; A Viswanathan; S M Rakich; T R Groover; S M Greenberg; E E Smith Journal: Neurology Date: 2006-07-11 Impact factor: 9.910
Authors: Franz Fazekas; Christian Enzinger; Reinhold Schmidt; Ulrike Grittner; Anne-Katrin Giese; Michael G Hennerici; Roman Huber; Gerhard J Jungehulsing; Manfred Kaps; Christof Kessler; Peter Martus; Jukka Putaala; Stefan Ropele; Christian Tanislav; Turgut Tatlisumak; Vincent Thijs; Bettina von Sarnowski; Bo Norrving; Arndt Rolfs Journal: Stroke Date: 2015-04-21 Impact factor: 7.914
Authors: Aleksandra Pikula; Alexa S Beiser; Charles DeCarli; Jayandra J Himali; Stephanie Debette; Rhoda Au; Jacob Selhub; Geoffrey H Toffler; Thomas J Wang; James B Meigs; Margaret Kelly-Hayes; Carlos S Kase; Philip A Wolf; Ramachandran S Vasan; Sudha Seshadri Journal: Circulation Date: 2012-03-28 Impact factor: 29.690
Authors: M E Gurol; M C Irizarry; E E Smith; S Raju; R Diaz-Arrastia; T Bottiglieri; J Rosand; J H Growdon; S M Greenberg Journal: Neurology Date: 2006-01-10 Impact factor: 9.910
Authors: N S Rost; R M Rahman; A Biffi; E E Smith; A Kanakis; K Fitzpatrick; F Lima; B B Worrall; J F Meschia; R D Brown; T G Brott; A G Sorensen; S M Greenberg; K L Furie; J Rosand Journal: Neurology Date: 2010-11-09 Impact factor: 9.910
Authors: Cathy R Zhang; Lisa Cloonan; Kaitlin M Fitzpatrick; Allison S Kanakis; Alison M Ayres; Karen L Furie; Jonathan Rosand; Natalia S Rost Journal: J Stroke Cerebrovasc Dis Date: 2014-11-06 Impact factor: 2.136
Authors: Yelong Shen; Bin Zhao; Lirong Yan; Kay Jann; Guangbin Wang; Junli Wang; Bao Wang; Josef Pfeuffer; Tianyi Qian; Danny J J Wang Journal: Front Neurol Date: 2017-12-22 Impact factor: 4.003
Authors: Julia Krämer; Felix Glaser; Martin Hasselblatt; Eva Brand; Christian Pogoda; Malte Lenders; Heinz Wiendl; Sven G Meuth; Thomas Duning Journal: Front Immunol Date: 2020-12-14 Impact factor: 7.561
Authors: James D Stefaniak; Laura M Parkes; Adrian R Parry-Jones; Gillian M Potter; Andy Vail; Ana Jovanovic; Craig J Smith Journal: Neurology Date: 2018-09-12 Impact factor: 9.910